Q4 & FY 2025 Earnings Presentation February 25, 2026 © 2026 Veracyte, Inc. All rights reserved. 1 Forward-looking statements and non-GAAP information This presentation contains forward-looking statements, including, but not limited to our statements related to our plans, objectives, and expectations (financial and otherwise), including with respect to our 2025 and 2026 financial and operating results; our assumptions for future revenue growth; plans and timing of the release of version 2 of our Veracyte tra ...

Financial Performance & Growth - Veracyte achieved approximately $516 million in total revenue for 2025, with a 17% testing revenue growth[12] - The company expects to achieve greater than 25% adjusted EBITDA in 2025[14] - Veracyte anticipates revenue between $570 million and $582 million in 2026, representing a 10-13% year-over-year growth[61] - The company projects a 14-16% year-over-year testing growth in 2026[61] - The company anticipates approximately 25% adjusted EBITDA margin in 2026[61] Product & Market Expansion - Over 800,000 patients have been served with Veracyte's tests to date[12] - Decipher Prostate has achieved approximately 33% market penetration in the U S[19] - Afirma has achieved approximately 38% market penetration in the U S thyroid cancer market[31] - The company plans to launch TrueMRD for muscle-invasive bladder cancer (MIBC) and Prosigna LDT in 2026[64] - Veracyte is developing IVD versions of its tests, including Decipher qPCR and Prosigna NGS, for geographic expansion[54]

Financial Performance - Total revenue increased to $132 million in Q3 2025, a 14% year-over-year growth compared to $116 million in Q3 2024[10] - Testing revenue reached $128 million in Q3 2025, a 17% year-over-year increase from $110 million in Q3 2024[10] - Adjusted EBITDA margin was 30.1% in Q3 2025, compared to 23.6% in Q3 2024[34] - The company raised full-year revenue guidance to $506 - $510 million and adjusted EBITDA margin expectations to over 25%[36] - Cash and short-term investments increased to $366 million at the end of Q3 2025, compared to $274 million in Q3 2024[34] Testing Volume and Growth - Testing volume increased to 43,700 in Q3 2025, a 19% year-over-year growth compared to 36,800 in Q3 2024[10] - Decipher test quarterly volume continued to grow, with a 26% increase[16] - Afirma test quarterly volume also experienced growth, with a 13% increase[21] Strategic Initiatives and Product Development - The company is transitioning to v2 Veracyte transcriptome to improve operational efficiency[14] - Commercial launch of TrueMRD for muscle invasive bladder cancer (MIBC) is on track for the first half of 2026[25] - Prosigna LDT launch is on track for mid-2026 in the CLIA lab[26]